Its latest quarterly revenue reached 3.11M, representing a year-over-year increase of 9.51%, while its net profit experienced a year-over-year increase of 16.23%.
The current valuation score of United-Guardian Inc is 7.66. Its current P/E ratio is 13.92, which is 60.19% below the recent high of 22.29 and 24.24% above the recent low of 10.54.
No earnings forecast score is currently available for United-Guardian Inc. The Pharmaceuticals industry's average is 7.81.
The current price momentum score of United-Guardian Inc is 2.60. Currently, the stock price is trading between the resistance level at 7.52 and the support level at 6.90, making it suitable for range-bound swing trading.
The latest institutional shareholding proportion is 24.63%, representing a quarter-over-quarter increase of 9.77%. The largest institutional shareholder is James Simons, holding a total of 166.77K shares, representing 0.00% of shares outstanding, with 36.21% decrease in holdings.
The current risk assessment score of United-Guardian Inc is 4.62. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.